Immunohistochemistry is a process that involves selectively identifying antigens in cells of a tissue section by exploiting the principle of antibodies binding specifically to antigens in biological tissues. Its principle is based on the affinity of an antibody towards its specific antigen.

The personalized medicine and immunotherapy in oncology has become the most demanding area of cancer treatment. Apart from the molecular approaches, Immunohistochemistry IHC is an important tool for selection of personalized medicine and to reach a definite diagnosis negating the subjectivevariations.

• I3T uses IHC for the determination of the sub-type of cancer and subsequent personalized drug selection, to identify carcinoma or sarcoma or lymphoma or mixed tumors like carcinosarcoma or adeno-squamous carcinoma etc.
• It can decide the origin of a tumors (primary or metastatic) even in undifferentiated type. It can identify Carcinoid (Neuroendocrine)tumors.
• It plays crucial role in clinical management of breast cancer (ER, Ki67), Malignant melanoma (VEGF), Head and neck cancer (p63), Cervical cancer, Ovarian cancer,etc.
• The lab is well-equipped with high-end instruments including digital pathology, Tissue microarray,etc.